Close Menu

Genetic Technologies

News items for the in vitro diagnostics industry for the week of May 25, 2020.

The company plans to use the proceeds for general product R&D, for reimbursement studies in the US, and for preparation for potential COVID-19 testing.

News items for the in vitro diagnostics industry for the week of April 20, 2020. 

The funds will be used to launch new products in the US, as well as for R&D activities including the development of polygenic risk tests with partner TGen.

News items for the in vitro diagnostics industry for the week of April 6, 2020.

The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.

The company will not be allowed to submit another plan for meeting the Nasdaq's listing requirements.

The Australian firm will use the proceeds for R&D, expansion in China, and to fund the development of polygenic risk tests with TGen in the US.

The company, which also trades on the Australian Securities Exchange, has 45 days to submit a plan to the Nasdaq as to regaining compliance.

The partners will work together on a US commercialization strategy for Genetic Technologies' line of existing and future polygenic risk tests.

Pages